Bharat Biotech-covaxin

Showing of 1 - 20 from 5 results
Bharat Biotech-covaxin - Total results - 5
Coronavirus vaccine may hit Indian market by first quarter of 2021, says health minister Harsh Vardhan
India

Coronavirus vaccine may hit Indian market by first quarter of 2021, says health minister Harsh Vardhan

Two homegrown vaccine candidates — Covaxin by Bharat Biotech and ZyCOV-D by Zydus Cadila — have almost finished the phase II clinical trials

Emerging landscape of COVID-19 vaccines in India, 14 Aug: Bharat Bio, Zydus move to Phase 2; Biological E, Bayor College tie up for COVID-19 vaccine
India

Emerging landscape of COVID-19 vaccines in India, 14 Aug: Bharat Bio, Zydus move to Phase 2; Biological E, Bayor College tie up for COVID-19 vaccine

Over a dozen Indian companies are in partnership with other firms and institutes to bring a preventive vaccine into global markets by 2021.

Coronavirus Updates: BMC sero-survey in three wards shows 57% prevalence of COVID-19 in slums, 16% in other areas
India

Coronavirus Updates: BMC sero-survey in three wards shows 57% prevalence of COVID-19 in slums, 16% in other areas

Coronavirus LIVE Updates: The BMC on Tuesday said that a serological surveillance for COVID-19 infection was commissioned by NITI-Aayog, Municipal Corporation of Greater Mumbai and Tata Institute of Fundamental Research.

Scientists caution govt over plans to fast-track 'Made in India' vaccine, COVAXIN
India

Scientists caution govt over plans to fast-track 'Made in India' vaccine, COVAXIN

A virologist said that a vaccine normally takes at least 12-18 months to pass all necessary clinical trial phases while the company developing it has just over a month to wrap up everything

COVID-19 vaccine: ICMR urges institutes chosen for Bharat Biotech's COVAXIN to complete recruitment for human trials by 7 July
India

COVID-19 vaccine: ICMR urges institutes chosen for Bharat Biotech's COVAXIN to complete recruitment for human trials by 7 July

The ICMR envisages launching the vaccine for public health use by 15 August after completion of all clinical trials, as per a letter to institutions conducting trials.